Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia
← catalyst calendarNCT07607600 · readout in 1,418 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
100estimated
Sites
23
Countries
Australia, Canada, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-07 | estimated | When the study began enrolling |
| Primary completion | 2030-07-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-07 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- X-linked Hypophosphatemia (XLH)
Intervention
- Other: No treatment given
Primary outcome
what the primary-completion date above is the date OFAverage Trough Serum Phosphate Concentration
measured From baseline to last assessment (Up to 3 years)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed